Sort   by:  
 Page size 
UnknownPatterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
Not available
S-EPMC9547952 | biostudies-literature
UnknownIdentifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Not available
S-EPMC10514205 | biostudies-literature
UnknownHealth-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors.
Not available
S-EPMC10165614 | biostudies-literature
UnknownReal-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Not available
S-EPMC10412575 | biostudies-literature
UnknownNew comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
Not available
S-EPMC12811452 | biostudies-literature
UnknownPeripheral-blood stem cells versus bone marrow from unrelated donors.
Not available
S-EPMC3816375 | biostudies-literature
UnknownMulticenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Not available
S-EPMC10149622 | biostudies-literature
UnknownFive-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Not available
S-EPMC12783362 | biostudies-literature
UnknownThe impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.
Not available
S-EPMC12789570 | biostudies-literature
UnknownAutologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Not available
S-EPMC7993097 | biostudies-literature
Sort   by:  
 Page size